CN105745207A - 使用PI3Kα抑制剂的增强的治疗方案 - Google Patents

使用PI3Kα抑制剂的增强的治疗方案 Download PDF

Info

Publication number
CN105745207A
CN105745207A CN201480063176.XA CN201480063176A CN105745207A CN 105745207 A CN105745207 A CN 105745207A CN 201480063176 A CN201480063176 A CN 201480063176A CN 105745207 A CN105745207 A CN 105745207A
Authority
CN
China
Prior art keywords
alpha inhibitor
pi3k alpha
days
pi3k
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480063176.XA
Other languages
English (en)
Chinese (zh)
Inventor
F·邹仁
C·帕特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of CN105745207A publication Critical patent/CN105745207A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201480063176.XA 2013-10-03 2014-10-02 使用PI3Kα抑制剂的增强的治疗方案 Pending CN105745207A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361886623P 2013-10-03 2013-10-03
US61/886,623 2013-10-03
US201462054879P 2014-09-24 2014-09-24
US62/054,879 2014-09-24
PCT/US2014/058926 WO2015051193A1 (en) 2013-10-03 2014-10-02 ENHANCED TREATMENT REGIMENS USING PI3Kα INHIBITORS

Publications (1)

Publication Number Publication Date
CN105745207A true CN105745207A (zh) 2016-07-06

Family

ID=52779165

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480063176.XA Pending CN105745207A (zh) 2013-10-03 2014-10-02 使用PI3Kα抑制剂的增强的治疗方案

Country Status (6)

Country Link
US (1) US20160287601A1 (enExample)
EP (1) EP3052493A4 (enExample)
JP (1) JP2016536282A (enExample)
CN (1) CN105745207A (enExample)
CA (1) CA2925523A1 (enExample)
WO (1) WO2015051193A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120550330A (zh) * 2025-07-29 2025-08-29 四川省肿瘤医院 经皮穴位电刺激调控免疫检查点系统及其方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL285928B2 (en) 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use
CN113194752A (zh) 2018-06-01 2021-07-30 康奈尔大学 Pi3k相关疾病或病症的组合疗法
EP3993786A1 (en) * 2019-07-02 2022-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prophylactic treatment of cancer in patients suffering from pancreatitis
JP2025521677A (ja) * 2022-07-06 2025-07-10 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 増殖性糸球体腎炎を処置するための方法
WO2025045915A1 (en) * 2023-08-29 2025-03-06 Institut National de la Santé et de la Recherche Médicale Methods for inducing muscle hypertrophy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011017687A1 (en) * 2009-08-06 2011-02-10 Ray Partha S Diagnosis of primary and metastatic basal-like breast cancer and other cancer types
WO2011022439A1 (en) * 2009-08-17 2011-02-24 Intellikine, Inc. Heterocyclic compounds and uses thereof
CN102089007A (zh) * 2008-07-11 2011-06-08 诺瓦提斯公司 (a)磷酸肌醇3-激酶抑制剂和(b)ras/raf/mek通路调节剂的组合产品
WO2013071271A1 (en) * 2011-11-11 2013-05-16 Qualcomm Incorporated Device and method to perform memory operations at a clock domain crossing
WO2013078440A2 (en) * 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403820B2 (en) * 2011-11-11 2016-08-02 Intellikine Llc Kinase inhibitor polymorphs

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102089007A (zh) * 2008-07-11 2011-06-08 诺瓦提斯公司 (a)磷酸肌醇3-激酶抑制剂和(b)ras/raf/mek通路调节剂的组合产品
WO2011017687A1 (en) * 2009-08-06 2011-02-10 Ray Partha S Diagnosis of primary and metastatic basal-like breast cancer and other cancer types
WO2011022439A1 (en) * 2009-08-17 2011-02-24 Intellikine, Inc. Heterocyclic compounds and uses thereof
WO2013071271A1 (en) * 2011-11-11 2013-05-16 Qualcomm Incorporated Device and method to perform memory operations at a clock domain crossing
WO2013078440A2 (en) * 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120550330A (zh) * 2025-07-29 2025-08-29 四川省肿瘤医院 经皮穴位电刺激调控免疫检查点系统及其方法
CN120550330B (zh) * 2025-07-29 2025-10-24 四川省肿瘤医院 经皮穴位电刺激调控免疫检查点系统及其方法

Also Published As

Publication number Publication date
EP3052493A4 (en) 2017-06-14
JP2016536282A (ja) 2016-11-24
EP3052493A1 (en) 2016-08-10
CA2925523A1 (en) 2015-04-09
US20160287601A1 (en) 2016-10-06
WO2015051193A1 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
JP6130391B2 (ja) Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
JP6047149B2 (ja) 併用の医薬組成物およびその使用
US8513266B2 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha
JP6114296B2 (ja) 複数の医薬品を使用した治療レジメン
US20230100137A1 (en) Methods of treating and preventing alloantibody driven chronic graft versus host disease
CN106456777A (zh) 结合物
CN105745207A (zh) 使用PI3Kα抑制剂的增强的治疗方案
JP2016512835A (ja) キナーゼ阻害剤の組み合わせ及びそれらの使用
US11576919B2 (en) Treatment of breast cancer using combination therapies comprising an ATP competitive AKT inhibitor, a CDK4/6 inhibitor, and fulvestrant
TW201642859A (zh) Ｍｄｍ２抑制劑及ｂｔｋ抑制劑之倂用治療法
US20250041300A1 (en) Pharmaceutical combination comprising abemaciclib and a pi3k and/or a mtor inhibitor for the treatment of mantle cell lymphoma
JP2015515476A (ja) Ｐｉ３ｋ阻害剤及びｍｅｋ阻害剤を使用する癌の治療方法
TW201625263A (zh) 利用ＰＩ３Ｋα抑制劑與紫杉烷之組合治療
CN118632696A (zh) 包含fgfr抑制剂和kras抑制剂的组合疗法
OA17142A (en) Methods for treating cancer using PI3K inhibitor and MEK inhibitor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160706